Company intelligence / Profile preview

InnoMedica

Ownership: Private
Employees: ~51
Development stage: Phase 1

Overview

The company has treated 43 cancer patients and 21 Parkinson's patients in clinical trials. For Parkinson's disease, they have demonstrated remarkable results including crossing the blood-brain barrier, offering sustained symptom improvement and halting disease progression. In cancer therapy, their lipid nanoparticles significantly reduce side effects while increasing efficacy[2][5][6].

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Nanoparticle drug delivery systemLiposomal technology
Industry: Biotech

Drug pipeline

4 assets

talineuren

3 more assets in the full pipeline.

Request access →

Partnerships

International and national research collaborations

Beyond the preview

Go deeper on InnoMedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoMedica.

Explore the full profile